Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -83.03% is 103% below its 3-year average of -40.84%, near the low end of its 3-year range (-83.03%–-18.56%).
As of the fiscal period ended Tuesday, June 30, 2026. 40.73% below its 12-month average of -59.00%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -83.03%.
RETURN ON EQUITY (ROE)
-83.03%
RETURN ON EQUITY (ROE) AVG TTM
-59.00%
RETURN ON EQUITY (ROE) AVG 3Y
-42.86%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-40.73%
CURRENT VS 3Y AVG
-93.71%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.89%
median of 684 covered companies
CURRENT VS SECTOR MEDIAN
-103.05%
vs the sector median at left
Metagenomi, Inc. Common Stock
Market Cap
$40.09M
Return on Equity (ROE)
-83.03%
TTM Avg
-59.00%
3Y Avg
-42.86%
5Y Avg
N/A
Market Cap
$40.44M
Return on Equity (ROE)
-66.47%
TTM Avg
-61.13%
3Y Avg
-30.57%
5Y Avg
-24.45%
Market Cap
$40.06M
Return on Equity (ROE)
14.51%
TTM Avg
6.28%
3Y Avg
-34.57%
5Y Avg
-35.24%
Market Cap
$38.61M
Return on Equity (ROE)
-140.36%
TTM Avg
-216.21%
3Y Avg
-112.57%
5Y Avg
-76.80%
Market Cap
$42.11M
Return on Equity (ROE)
-8.23%
TTM Avg
-18.98%
3Y Avg
-38.34%
5Y Avg
-43.89%
Market Cap
$37.72M
Return on Equity (ROE)
-28.65%
TTM Avg
-189.41%
3Y Avg
-194.44%
5Y Avg
-158.64%
Market Cap
$43.16M
Return on Equity (ROE)
-102.45%
TTM Avg
30.59%
3Y Avg
217.16%
5Y Avg
155.68%
Market Cap
$37.60M
Return on Equity (ROE)
-160.05%
TTM Avg
-184.57%
3Y Avg
-168.71%
5Y Avg
-141.15%
Market Cap
$37.08M
Return on Equity (ROE)
-476.77%
TTM Avg
-979.99%
3Y Avg
-646.46%
5Y Avg
-421.61%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Metagenomi, Inc. Common Stock (MGX) | $40.09M | -83.03% | -59.00% | -42.86% | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.44M | -66.47% | -61.13% | -30.57% | -24.45% |
| Nephros, Inc. (NEPH)vs › | $40.06M | 14.51% | 6.28% | -34.57% | -35.24% |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.61M | -140.36% | -216.21% | -112.57% | -76.80% |
| Precipio, Inc. (PRPO)vs › | $42.11M | -8.23% | -18.98% | -38.34% | -43.89% |
| Incannex Healthcare Limited (IXHL)vs › | $37.72M | -28.65% | -189.41% | -194.44% | -158.64% |
| BioStem Technologies, Inc. (BSEM)vs › | $43.16M | -102.45% | 30.59% | 217.16% | 155.68% |
| Edesa Biotech, Inc. (EDSA)vs › | $37.60M | -160.05% | -184.57% | -168.71% | -141.15% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $37.08M | -476.77% | -979.99% | -646.46% | -421.61% |
| SANUWAVE Health Inc. (SNWV)vs › | $43.17M | 513.56% | 488.17% | 265.30% | 226.12% |
ROE
-83.0%
ROA
-53.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -83.03% |
| 2026-03-31 | -62.33% |
| 2025-12-31 | -55.40% |
| 2025-09-30 | -49.73% |
| 2025-06-30 | -44.49% |
| 2025-03-31 | -36.65% |
| 2024-12-31 | -33.24% |
| 2024-09-30 | -28.91% |
| 2024-06-30 | -27.84% |
| 2024-03-31 | -28.03% |
| 2023-06-30 | -21.82% |
| 2023-03-31 | -18.56% |
